Redeye comments on the rights issue of SEK170m announced yesterday.
Redeye updates its valuation model following Xspray's announcement of SEK235m in financing and the c...
Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits on...
Sales down 14% y-o-y as restaurant market headwinds intensify GC&MP strength improves mix, cost cont...
Redeye gives a brief comment on today’s news regarding Tesofensine, indicating that Tesofensine has ...
Tessin tillhandahåller en digital investeringsplattform för säkerställda fastighetslån.
Administer's net sales declined by 3.9% y/y, reflecting the challenging market conditions that have ...
STENOCARE published on November 5th the company’s Q3-report for 2024.
Potentiell vändpunkt Adtraction minskade omsättningen med 17,5 procent i det tredje kvartalet.
Redeye continues to be positive to Bredband2 following a Q3 report that beat our estimates by delive...
iZafe Group levererade ett kvartal i linje med Analysguidens prognos.
EBITA -1% vs FactSet consensus, +27% y-o-y Strong order book of EUR 382m (+108% y-o-y) Neutral est c...
Sales -12% and EBIT -2m vs. ABGSCe Weak performance in NW&FT, as market headwinds intensify Expect c...
Sales -6%, adj. EBIT -11% vs. FactSet consensus in Q3 We expect consensus to lower EBIT estimates by...
Redeye comments on G5’s Q3-results which saw somewhat softer topline than expected while gross margi...
